Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Aroa Biosurgery Limited	
ARBN	638 867 473	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Ward
Date of last notice	31 March 2023

Part 1 - Change of director's relevant interests in securities

 $In the \ case \ of \ a \ trust, this \ includes \ interests \ in \ the \ trust \ made \ available \ by \ the \ responsible \ entity \ of \ the \ trust$

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	22 August 2024	4
No. of securities held prior to change	< <u>Arawai No 2</u>	Fully Paid Ordinary Shares Options exercisable at \$0.75 expiring 23 July 2025 Options exercisable at \$Nil expiring 13 November 2027 Options exercisable at \$1.165 expiring on 13 November 2027 Options exercisable at \$1.165 expiring 29 February 2028 Options exercisable at \$1.165 expiring 29 February 2028 Options exercisable at \$Nil expiring 29 February 2028

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Class	Performance Rights	
Number acquired	961,255	
Number disposed	-	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil	
No. of securities held after change	Indirect Mr Brian Ward & Mrs Tracey Ward <arawa 2="" a="" c="" no=""></arawa>	
	33,125,800 Fully Paid Ordinary Shares 3,132,525 Options exercisable at \$0.75 expiring 23 July 2025	
	1,217,610 Options exercisable at \$Nil expiring 13 November 2027	
	649,695 Options exercisable at \$1.165 expiring on 13 November 2027	
	254,972 Options exercisable at \$1.165 expiring 29 February 2028	
	453,206 Options exercisable at \$Nil expiring 29 February 2028	
	961,255 Performance Rights expiring 1 August 2027	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued on 22 August 2024 pursuant to shareholder approval received at the Annua General Meeting held on 23 July 2024.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder	-
(if issued securities)	
Date of change	-
No. and class of securities to which interest	-
related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	-
Interest disposed	-
Value/Consideration	-
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	-

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.